Research programme: PSC-NK cell therapies - HebeCell
Latest Information Update: 07 Sep 2023
At a glance
- Originator Hebecell
- Class Antineoplastics; Gene therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 16 Aug 2023 Hebecell has patents pending for "Methods and systems for manufacturing hematopoietic lineage cells" in Brazil, China, Singapore, South Korea, the US, Japan, Australia, the Europe, Canada, Israel and multiple countries worldwide
- 11 Aug 2023 Hebecell in-licenses Geno-Writing™ technology from Logomix
- 11 Aug 2023 Early research in Cancer in USA (Parenteral)